Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITI-012
- Development stage
- Preclinical
- Lead developer
- Intra-Cellular Therapies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ITI-012 is a small molecule inhibitor of Casein Kinase 1 (CK1), originally developed by Intra-Cellular Therapies. CK1 is a serine/threonine kinase family implicated in various cellular processes, including circadian rhythm regulation and neuropsychiatric disorders. The ITI-012 series targets these kinases, and preclinical development focused on indications such as Alzheimer’s disease and other central nervous system disorders[7][14].
02
Targets
CSNK1G3 (Casein kinase 1 gamma 3)
Beyond the preview
Go deeper on ITI-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITI-012.